These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 19927329)

  • 1. C3, C5, and factor B bind to chitosan without complement activation.
    Marchand C; Bachand J; Périnêt J; Baraghis E; Lamarre M; Rivard GE; De Crescenzo G; Hoemann CD
    J Biomed Mater Res A; 2010 Jun; 93(4):1429-41. PubMed ID: 19927329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathways of complement activation in membranoproliferative glomerulonephritis and allograft rejection.
    Fearon DT; Daha MR; Strom TB; Weiler JM; Carpenter CB; Austen KF
    Transplant Proc; 1977 Mar; 9(1):729-39. PubMed ID: 325806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific inhibitor of complement (C5)-derived chemotactic activity in systemic lupus erythematosus related antigenically to the Bb fragment of human factor B.
    Perez HD; Hooper C; Volanakis J; Ueda A
    J Immunol; 1987 Jul; 139(2):484-9. PubMed ID: 3648093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of complement fragment C5a in milk is variable among cows.
    Rainard P; Poutrel B
    J Dairy Sci; 2000 May; 83(5):945-51. PubMed ID: 10821569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of a neutrophil chemotactic agent by spermatozoa: role of complement and regulation by seminal plasma factors.
    Clark RA; Klebanoff SJ
    J Immunol; 1976 Oct; 117(4):1378-86. PubMed ID: 977954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alterations in C3 activation and binding caused by phosphorylation by a casein kinase released from activated human platelets.
    Ekdahl KN; Nilsson B
    J Immunol; 1999 Jun; 162(12):7426-33. PubMed ID: 10358196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Group B streptococci inhibit the chemotactic activity of the fifth component of complement.
    Hill HR; Bohnsack JF; Morris EZ; Augustine NH; Parker CJ; Cleary PP; Wu JT
    J Immunol; 1988 Nov; 141(10):3551-6. PubMed ID: 3053900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of the C3b binding site in a recombinant vWF-A domain of complement factor B by surface-enhanced laser desorption-ionisation affinity mass spectrometry and homology modelling: implications for the activity of factor B.
    Hinshelwood J; Spencer DI; Edwards YJ; Perkins SJ
    J Mol Biol; 1999 Nov; 294(2):587-99. PubMed ID: 10610782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The activation of C5 in the fluid phase and in the absence of C3 through the classical pathway of the complement system.
    Kitamura H; Tsuboi M; Nagaki K
    Immunology; 1986 Jul; 58(3):459-65. PubMed ID: 3733147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Binding of C3 fragments on top of adsorbed plasma proteins during complement activation on a model biomaterial surface.
    Andersson J; Ekdahl KN; Lambris JD; Nilsson B
    Biomaterials; 2005 May; 26(13):1477-85. PubMed ID: 15522749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preservation of C3, C5, and C5a functional activities by a new radiolabeling method; demonstration of C5 products in complement-activated serum.
    Kreutzer DL; Kunkel S; Ward PA; Showell H; McLean RH
    J Immunol; 1979 Nov; 123(5):2278-82. PubMed ID: 489983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The many effects of complement C3- and C5-binding proteins in renal injury.
    Puri TS; Quigg RJ
    Semin Nephrol; 2007 May; 27(3):321-37. PubMed ID: 17533009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantification of C5a/C5a(desArg) in bovine plasma, serum and milk.
    Rainard P; Sarradin P; Paape MJ; Poutrel B
    Vet Res; 1998; 29(1):73-88. PubMed ID: 9559522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The release of C5a in complement-activated serum does not require C6.
    Biesecker G; Wagner JL; Hugli TE
    J Immunol; 1989 Aug; 143(4):1228-32. PubMed ID: 2545783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absence of induction of IL-1 production in human monocytes by complement fragments.
    Arend WP; Massoni RJ; Niemann MA; Giclas PC
    J Immunol; 1989 Jan; 142(1):173-8. PubMed ID: 2783323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trypsin-activated complex of human factor B with cobra venom factor (CVF), cleaving C3 and C5 and generating a lytic factor for unsensitized guinea pig erythrocytes. I. Generation of the activated complex.
    Miyama A; Kato T; Horai S; Yokoo J; Kashiba S
    Biken J; 1975 Dec; 18(4):193-204. PubMed ID: 1218074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of C5a in the absence of C3: a new complement activation pathway.
    Huber-Lang M; Sarma JV; Zetoune FS; Rittirsch D; Neff TA; McGuire SR; Lambris JD; Warner RL; Flierl MA; Hoesel LM; Gebhard F; Younger JG; Drouin SM; Wetsel RA; Ward PA
    Nat Med; 2006 Jun; 12(6):682-7. PubMed ID: 16715088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relative inefficiency of terminal complement activation.
    Bhakdi S; Fassbender W; Hugo F; Carreno MP; Berstecher C; Malasit P; Kazatchkine MD
    J Immunol; 1988 Nov; 141(9):3117-22. PubMed ID: 3262681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C5 chemotactic fragment induces leukocyte production of tissue factor activity: a link between complement and coagulation.
    Muhlfelder TW; Niemetz J; Kreutzer D; Beebe D; Ward PA; Rosenfeld SI
    J Clin Invest; 1979 Jan; 63(1):147-50. PubMed ID: 762243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complement-induced expression of cryptic receptors on the neutrophil surface: a mechanism for regulation of acute inflammation in trauma.
    Solomkin JS; Cotta LA; Ogle JD; Brodt JK; Ogle CK; Satoh PS; Hurst JM; Alexander JW
    Surgery; 1984 Aug; 96(2):336-44. PubMed ID: 6087484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.